 |
 |
In July, Titan Pharmaceuticals Inc. announced its Phase IIb trial of Parkinson's disease therapy Spheramine "failed to meet its primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up." Soon after its partner Bayer Pharm. announced it would not continue developing the product. However some people in the trial did improve from the experimental treatment - which involved insertion of retinal cells into the brain. As in the GDNF halted trials, the voices of the patients were unheard. Forbes reported on this story and posted comments from PWP on the halt of Spheramine development. additional comments are being accepted. See: http://www.forbes.com/afxnewslimited/feeds/afx/2008/07/02/afx5176391.html ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn